Neumora Therapeutics, Inc. has announced the launch of a Phase 1 clinical study evaluating NMRA-861 in healthy adult participants and adults with stable schizophrenia. NMRA-861 is a highly potent and selective positive allosteric modulator (PAM) of the M4 muscarinic receptor with potential best-in-class pharmacology that Neumora plans to develop for the treatment of schizophrenia and other neuropsychiatric disorders.
The Warren Center for Neuroscience Drug Discovery (WCNDD) played a key role in discovering and characterizing this compound, which has shown strong early results. Through Vanderbilt Center for Technology and Commercialization (CTTC), Neumora exclusively licensed certain intellectual property rights related to NMRA-861.
Michael Villalobos, CTTC Assistant Director of Life Sciences Licensing, highlights the achievement: “Congratulations to the Neumora and the WCNDD teams. On behalf of CTTC, we are thrilled to witness the groundbreaking translation of academic drug discovery into clinical reality. This Phase 1 study validates the innovative research originating from the WCNDD and would not be possible without the persistent efforts of a visionary company like Neumora.”
This milestone marks another promising step in advancing innovative neuropsychiatric therapeutics from academic discovery to clinical development.
Read the full press release here.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.